Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T- lymphocyte epitope from ovalbumin

Infection and Immunity

Volumn 66, Issue 2, 1998, Pages 615-619

  Ballard, Jimmy D ^a   Doling, Amy M ^a   Beauregard, Kathryn ^a   John Collier, R ^a   Starnbach, Michael N ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; OVALBUMIN;

ADOPTIVE IMMUNOTHERAPY; ANTHRAX; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; EPITOPE MAPPING; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SPLEEN CELL; TARGET CELL;

EID: 0031932474     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.2.615-619.1998     Document Type: Article

References (36)

1. Ahmed, R., and D. Gray, 1996. Immunological memory and protective immunity: understanding their relation. Science 272:5-1-60.
2. Arora, N., K. R. Klimpel, Y. Singh, and S. H. Leppla. 1992. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J. Biol. Chem. 267:15542-15548.
3. Arora, N., and S. H. Leppla. 1993. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J. Biol. Chem. 268:3334-3341.
4. Ballard, J. D., R. J. Collier, and M. N. Starnbach. 1996. Anthrax toxinmediated delivery of a cytotoxic T-cell epitope in vivo. Proc. Nat. Acad. Sci. USA 93:12531-12534.
5. Celis, E., V. Tsai, C. Crimi, R. DeMars, P. A. Wentworth, R. W. Chesnut, H. M. Grey, A. Sette, and H. M. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91:2105-2109.
6. Celluzzi, C M., and L. D. Falo, Jr. 1997. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J. Invest. Dermatol. 108:716-720.
7. Clark, W. R., C. M. Walsh, A. A. Glass, F. Hayashi, M. Malloubian, and R. Ahmed. 1995. Molecular pathways of CTL-mediated cytotoxicity. Immunol. Rev. 146:33-44.
8. Coligan, J. E., A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober. 1994. Current protocols in immunology, vol. 1. Green Publishing Co., New York, N.Y.
9. DiMaio, J. M., P. Van Trigt, J. W. Gaynor, R. D. Davis, E. Coveney, B. M. Clary, and H. K. Lyerly. 1995. Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma. Circulation 92(9 Suppl.): II202-II205.
10. Ertl, H. C. J., and Z. Xiang. 1996. Novel vaccine approaches. J. Immunol. 156:3579-3582.
11. Ferrari, G., K. King, K. Rathbun, C. A. Place, M. V. Packard, J. A. Bartlett, D. P. Bolognesi, and K. J. Weinhold. 1995. IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin. Exp. Immunol. 101:239-248.
12. Gordon, V. M., K. R. Klimpel, N. Arora, M. A. Henderson, and S. H. Leppla. 1995. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 63:82-87.
13. Gotch, F., A. Gallimore, and A. McMichael. 1996. Cytotoxic T cells-protection from disease progression-protection from infection. Immunol. Lett. 51:125-128.
14. Hanna, P., B. Kruskal, R. A. Ezekowitz, B. Bloom, and R. J. Collier. 1994. Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol. Med. 1:7-18.
15. Hanna, P. C., D. Acosta, and R. J. Collier. 1993. On the role of macrophages in anthrax. Proc. Natl. Acad, Sci. USA 90:10198-10201.
16. Heemels, M. T., and H. Ploegh. 1995. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu, Rev. Biochem. 64:463-491.
17. Heslop, H. E., C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney. 1996. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2:551-555.
18. Leppla, S. H. 1991. The anthrax toxin complex, p. 277-302. In J. Alouf (ed.), Sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y.
19. Leppla, S. H. 1984. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 17:189-198.
20. Lieberman, j., J. A. Fabry, P. Shankar, L. Beckett, and P. R. Skolnik. 1995. Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. AIDS Res. Hum. Retroviruses 11:257-271.
21. Lipford, G. B., S. Bauer, H. Wagner, and K. Heeg. 1995. In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine 13:313-320.
22. Lubaki, M. N., M. A. Egan, R. F. Siliciano, K. J. Weinhold, and R. C. Bollinger. 1994. A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res. Hum. Retroviruses 10:1427-1431.
23. Melief, C. J. M., and M. Kast. 1995. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 146:167-177.
24. Milne, J. C., S. R. Blanke, P. C. Hanna, and R. J. Collier. 1995. Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol. Microbiol. 15:661-666.
25. Mims, C. A., N. J. Dim mock, A. Nash, and J. Stephen. 1995. Mims' pathogenesis of infectious disease. Academic Press, Inc., San Diego, Calif.
26. Shen, H., M. K. Slifka, M. Matloubian, E. R. Jensen, R. Ahmed, and J. F. Miller. 1995. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc. Natl. Acad. Sci. USA 92:3987-3991.
27. Singh, Y., K. R. Klimpel, N. Arora, M. Sharma, and S. H. Leppla. 1994. The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. J. Biol. Chem. 269:29039-29046.
28. Splitter, G., S. Oliveira, M. Carey, C. Miller, J. Ko, and J. Covert. 1996. T lymphocyte mediated protection against facultative intracellular bacteria. Vet. Immunol. Immunopathol. 54:309-319.
29. Starnbach, M. N., and M. J. Bevan. 1994. Cells infected with Yersinia present an epitope to class I MHC-restricted CTL. J. Immunol. 153:1603-1612.
30. Starnbach, M. N., M. J. Bevan, and M. F. Lampe. 1994. Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. J. Immunol. 153:5183-5189.
31. Studier, F. W., and B. A. Moffatt. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189:113-130.
32. Thibault, C., H. Nelson, and A. I. Chapoval. 1996. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies. Int. J. Cancer 67:232-237.
33. Torpey, D. D., X. L. Huang, J. Armstrong, M. Ho, T. Whiteside, D. McMahon, G. Pazin, R. Heberman, P. Gupta, C. Tripoli, et al. 1993. Effects of adoptive immunotherapy with autologous CD8+ T lymphocytes on immunologic parameters: lymphocyte subsets and cytotoxic activity. Clin. Immunol. Immunopathol. 68:263-272.
34. Traversari, C., P. van der Bruggen, B. Van den Eynde, P. Hainaut, C. Lemoine, N. Ohta, L. Old, and T. Boon. 1992. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35:145-152.
35. White, W. I., D. R. Cassatt, J. Madsen, S. J. Burket, R. M. Woods, N. M. Wassef, C. R. Alvings, and S. Koenig. 1995. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine 13:1111-1122.
36. Whiteside, T. L., E. M. Elder, D. Moody, J. Armstrong, M. Ho, C. Rinaldo, X. Huang, D. Torpey, P. Gupta, D. McMahon, et al. 1993. Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus. Blood 81:2085-2092.